Cart
sales@molnova.com
Pyrabactin
CAS No. 419538-69-5
Pyrabactin( —— )
Catalog No. M24382 CAS No. 419538-69-5
Pyrabactin is a seed-selective abscisic acid (ABA) agonist, Novel PYL agonist; acting as a plant growth inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 123 | In Stock |
|
| 10MG | 176 | In Stock |
|
| 25MG | 302 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePyrabactin
-
NoteResearch use only, not for human use.
-
Brief DescriptionPyrabactin is a seed-selective abscisic acid (ABA) agonist, Novel PYL agonist; acting as a plant growth inhibitor.
-
DescriptionPyrabactin is a seed-selective abscisic acid (ABA) agonist, Novel PYL agonist; acting as a plant growth inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPYR/PYL/RCARs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number419538-69-5
-
Formula Weight377.26
-
Molecular FormulaC16H13BrN2O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10mg/mL (26.50 mM)
-
SMILESO=S(c(c1ccccc11)ccc1Br)(NCc1ncccc1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.González-Villagra J, et al. Evaluating the involvement and interaction of abscisic acid and miRNA156 in the induction of anthocyanin biosynthesis in drought-stressed plants. Planta. 2017 May 22.
molnova catalog
related products
-
Quercetin 3,3-dimeth...
Quercetin 3,3'-dimethyl ether possesses antioxidant acticity.
-
Sodium succinate
Sodium succinate is the sodium salt form of succinate which is an important metabolite at the cross-road of several metabolic pathways and involved in the formation and elimination of reactive oxygen species.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
